Cs4 for Pneumoconiosis Rehabilitation
NCT07932587, Not applicable, Not yet recruiting, Tung Leong FONG
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Cs4 for Pneumoconiosis Rehabilitation | ClinicalTrials.gov |
| NCT number | NCT07932587 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 84 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Tung Leong FONG | ClinicalTrials.gov |
| Conditions | Pneumoconiosis | ClinicalTrials.gov |
| Interventions | Cordyceps sinensis mycelium culture extract (Cs4), Matching Placebo (B) | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Forced Expiratory Volume in One Second/ Forced Vital Capacity (FEV1/FVC) ratio | from baseline to week 24 | Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) will be measured by trained, blinded assessors using standardized spirometry according to American Thoracic Society/European Respiratory Society standards. | ClinicalTrials.gov |
| Secondary | Forced Expiratory Volume in One Second (FEV1) | Baseline, week 12, week 24, and week 36 | Change from baseline in FEV1, measured in liters by spirometry according to American Thoracic Society/European Respiratory Society standards. | ClinicalTrials.gov |
| Secondary | Forced Vital Capacity (FVC) | Baseline, week 12, week 24, and week 36 | Change from baseline in FVC, measured in liters by spirometry according to American Thoracic Society/European Respiratory Society standards. | ClinicalTrials.gov |
| Secondary | Six-Minute Walk Distance (6MWD) | Baseline, week 12, week 24, and week 36 | Change from baseline in the total distance walked during the six-minute walk test, measured in meters. A longer distance indicates greater functional exercise capacity. | ClinicalTrials.gov |
| Secondary | St. George's Respiratory Questionnaire (SGRQ) Total Score | Baseline, week 12, week 24, and week 36 | Change from baseline in SGRQ total score, assessing overall impairment in respiratory health status. Scores range from 0 to 100, with higher scores indicating worse health status. | ClinicalTrials.gov |
| Secondary | Modified Medical Research Council (mMRC) Dyspnea Scale Score | Baseline, week 12, week 24, and week 36 | Change from baseline in mMRC Dyspnea Scale score, assessing limitations in daily activities caused by breathlessness. Scores range from 0 to 4, with higher scores indicating greater limitation. | ClinicalTrials.gov |
| Secondary | Leicester Cough Questionnaire (LCQ) Total Score | Baseline, week 12, week 24, and week 36 | Change from baseline in LCQ total score, assessing cough-related quality of life using 19 items across physical, psychological, and social domains. The total score ranges from 3 to 21, with higher scores indicating better quality of life. | ClinicalTrials.gov |
| Other | High-Sensitivity C-Reactive Protein (hs-CRP) Level | Baseline, week 24, and week 36 | Change from baseline in blood high-sensitivity C-reactive protein (hs-CRP) concentration, measured using an immunoturbidimetric assay. Change will be calculated separately at week 24 and week 36 by subtracting the baseline concentration from the concentration at each follow-up visit. | ClinicalTrials.gov |
| Other | Interleukin-6 (IL-6) Level | Baseline, week 24, and week 36 | Change from baseline in blood IL-6 concentration, measured using a high-sensitivity enzyme-linked immunosorbent assay (ELISA). Change will be calculated separately at week 24 and week 36 by subtracting the baseline concentration from the concentration at each follow-up visit. | ClinicalTrials.gov |
| Other | Malondialdehyde (MDA) Level | Baseline, week 24, and week 36 | Change from baseline in blood MDA level, assessed using a thiobarbituric acid reactive substances (TBARS) assay. Change will be calculated separately at week 24 and week 36 by subtracting the baseline value from the value at each follow-up visit. | ClinicalTrials.gov |
| Other | Superoxide Dismutase (SOD) Activity | Baseline, week 24, and week 36 | Change from baseline in blood SOD activity, measured using a colorimetric assay based on nitroblue tetrazolium reduction. Change will be calculated separately at week 24 and week 36 by subtracting the baseline activity from the activity at each follow-up visit. | ClinicalTrials.gov |
| Other | Glutathione Peroxidase (GPx) Activity | Baseline, week 24, and week 36 | Change from baseline in blood GPx activity, measured using a coupled enzyme assay based on nicotinamide adenine dinucleotide phosphate (NADPH) oxidation. Change will be calculated separately at week 24 and week 36 by subtracting the baseline activity from the activity at each follow-up visit. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)